EUVIMEDEUVIMED entdecken
Vergleichsstudie

Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database

Qingran Yan, Cosimo Bruni, Alexandru Garaiman, Carina Mihai, Suzana Jordan, Mike Oliver Becker, Muriel Elhai, Rucsandra Dobrota, Petelytska Liubov, Joerg Henes, Eric Hachulla, Elise Siegert und 16 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.01.014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Qingran Yan und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China; Department of Rheumatology, University…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Mycophenolic Acid, Cyclophosphamide, Rituximab. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Scholarship Council, Universität Zürich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) most frequently used for systemic sclerosis-associated interstitial lung disease (SSc-ILD). This post hoc study aimed to compare their effectiveness in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database. METHODS: We included radiologically confirmed SSc-ILD patients with treatment records for TCZ, RTX, MMF, or CYC. The primary endpoint was the change in forced vital capacity (FVC) percent predicted from baseline to follow-up. Analyses were adjusted for clinical and demographic characteristics, cotreatments, and follow-up duration using propensity score-based inverse probability of treatment weighting (IPTW). RESULTS: Nine hundred fifty-five patients with 997 treatment observations were included in the study. The median follow-up time was 11 months (IQR, 8-14 months). After IPTW, the changes in FVC percent predicted were not significantly different in the multigroup comparison (P = .101). Paired comparisons showed no significant difference. CYC was associated with stable FVC in logistic regression. For subgroup analysis, the treatment differences in change of FVC percent predicted among the 4 groups were not significant in patients with combination IS or previous exposure to TCZ, RTX, or conventional IS, as well as in current smokers or nonsmokers, and regardless of whether observations started either at the initiating or noninitiating stage of the treatment. CONCLUSIONS: In this first large real-world study, the effectiveness of TCZ, RTX, MMF, and CYC on FVC change in SSc-ILD patients was not statistically different.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicMycophenolic AcidCyclophosphamideRituximabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsLung Diseases, InterstitialHumansFemaleMaleMiddle AgedTreatment OutcomeDatabases, FactualVital CapacityAgedAdult

Substanzen

tocilizumabMycophenolic AcidCyclophosphamideRituximabAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China; Department of Rheumatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. Electr…
  • Department of Rheumatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Department of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany.
  • Department of Internal Medicine and Clinical Immunology, Referral Centre for Rare Systemic Auto-immune and Auto-inflammatory Diseases North North-West Mediterranean and Guadeloupe, University of Lille, Inserm, Unit 1286…
  • Department of Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Förderung

  • China Scholarship Council
  • Universität Zürich

Zitieren

APA

Yan, Q., Bruni, C., Garaiman, A., Mihai, C., Jordan, S., Becker, M. O., Elhai, M., Dobrota, R., Liubov, P., Henes, J., Hachulla, E., Siegert, E., Balbir-Gurman, A., Cuomo, G., Riemekasten, G., Heitmann, S., Beigi, D. M. R., Ullman, S., Sfikakis, P., …, & EUSTAR collaborators (2025). Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.01.014

Vancouver

Yan Q, Bruni C, Garaiman A, Mihai C, Jordan S, Becker MO, et al. Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.01.014

BibTeX
@article{Yan2025,
  author = {Yan, Qingran and Bruni, Cosimo and Garaiman, Alexandru and Mihai, Carina and Jordan, Suzana and Becker, Mike Oliver and Elhai, Muriel and Dobrota, Rucsandra and Liubov, Petelytska and Henes, Joerg and Hachulla, Eric and Siegert, Elise and Balbir-Gurman, Alexandra and Cuomo, Giovanna and Riemekasten, Gabriela and Heitmann, Stefan and Beigi, Davide Mohammad Reza and Ullman, Susanne and Sfikakis, Petros and Ingegnoli, Francesca and Bernardino, Vera and Truchetet, Marie-Elise and Vonk, Madelon and Galdo, Francesco Del and Hoffmann-Vold, Anna-Maria and Shuang, Ye and Distler, Oliver and EUSTAR collaborators, EUSTAR collaborators},
  title = {Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.01.014}
}
Kostenlos starten →